PALO ALTO, Calif., July 27 /PRNewswire/ -- Affymax, Inc., a clinical-stage pharmaceutical company, today announced the appointment of Ted W. Love, M.D., to the Company's board of directors. Dr. Love is currently chairman and chief executive officer of Nuvelo, Inc. .
"Ted Love is an experienced and highly-respected biotechnology industry executive who will be an exceptional addition to Affymax's board. He has successfully built Nuvelo into a company with a full pipeline of products in late-stage clinical trials, secured an outstanding partner for the company's lead product in Bayer HealthCare, strengthened Nuvelo's financial position, and is now preparing for commercialization," said Arlene M. Morris, president and chief executive officer of Affymax. "Also, Ted's previous experience at Genentech in accelerating the drug development process and helping bring products to market will be valuable to Affymax as we advance Hematide(TM), our lead product candidate, through clinical development and, if successful, into commercialization for the treatment of anemia in patients with chronic kidney disease and cancer."
In March 2001, Dr. Love was appointed president and chief executive officer of Nuvelo, a publicly traded biopharmaceutical company dedicated to improving the lives of patients through the discovery, development, and commercialization of novel drugs for acute cardiovascular and cancer therapy. He became chairman of the board of Nuvelo in September 2005. Dr. Love joined Nuvelo from Theravance, Inc., where he served as senior vice president of development. Previously, he spent six years at Genentech, Inc., where he held a number of senior management positions in medical affairs and product development and served as chairman of Genentech's Product Development Committee. As vice president of product development and regulatory affairs at Genentech, Dr. Love oversaw all drugs in development, including Herceptin, Rituxan, and TNKase.
Dr. Love also serves as a member of the boards of directors of Predix Pharmaceuticals, Inc., Santarus, Inc., and the California Healthcare Institute. In addition, he serves on the California Independent Citizens' Oversight Committee (ICOC), the 29-member board that oversees the $3 billion allocated to stem cell research authorized by Proposition 71.
Dr. Love earned his bachelor's degree in molecular biology from Haverford College and his medical degree from Yale Medical School.
About Affymax
Affymax, Inc. is a clinical-stage pharmaceutical company that is developing a pipeline of synthetic peptide-based drugs against clinically validated targets for the treatment of kidney diseases and cancer. Hematide(TM), the Company's first product candidate to enter the clinic, is a novel peptide-based drug designed to stimulate the production of red blood cells. It is in Phase 2 trials for the treatment of anemia associated with chronic kidney disease and cancer. For more information go to www.affymax.com.
Affymax, Inc.CONTACT: corporate, Mary Fermi, Senior Director, Commercial Development ofAffymax, Inc., +1-650-812-8722; or media, Jani Bergan of WeissCommPartners, +1-415-946-1064, or jbergan@weisscommpartners.com, for Affymax,Inc.
Web site: http://www.affymax.com/
